BABA
Alibaba Group Holding Limited
BABA has a slight edge over HZO overall, supported by lower modeled downside.
HZO
MarineMax, Inc.
HZO offers stronger fundamentals, but that advantage does not outweigh its weaker overall profile.
BABA Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Under pressure | |
| Weak | |
| Healthy |
BABA's balance sheet is currently healthy, and its revenue is stable, but its profitability and cash flow are under pressure.
HZO Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Stable | |
| Healthy | |
| Weak |
HZO's cash flow is currently healthy, and its profitability is stable, but its revenue and balance sheet are under pressure.
BABA PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 16x | $69.66 | -26% |
| Fair | 20x | $86.59 | -8.2% |
| Current | 21x | $94.36 | — |
| Expensive | 26x | $115 | +22% |
Historical ranges are pointers, not guarantees.
BABA's PE is 21x, but its earnings don't support one, so it isn't a reliable read right now.
HZO PE Valuation
HZO has no meaningful PE right now: it lost money over the past year.
BABA Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Strong growth | |
| Growth | |
| Strongly improving | |
| Limited | |
| Low |
BABA has the edge over HZO on the outlook, with more favorable revenue expectations.
HZO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Strong growth | |
| Stable | |
| Improving | |
| Limited | |
| Low |
Analysts expect HZO's earnings to grow and its profitability to improve, with its revenue holding steady. However, they disagree widely on these estimates.
BABA Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | $4.42 | -52% |
| Q1 2026 | $6.57 | -18% |
| Q4 2025 | $5.79 | -22% |
| Q3 2025 | $7.85 | +49% |
| Q2 2025 | $9.27 | +116% |
| Q1 2025 | $8.06 | +71% |
| Q4 2024 | $7.47 | +24% |
| Q3 2024 | $5.26 | -35% |
BABA has the edge over HZO in the latest year-over-year earnings comparison.
HZO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $1.61 | — |
| Q3 2026 | -$0.41 | +$1.02 |
HZO lost $0.41 per share over the past year, a smaller loss than the year before.
BABA Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $40.2B | +8.3% |
| Q1 2026 | $36.5B | +2.9% |
| Q4 2025 | $42.7B | +1.7% |
| Q3 2025 | $37.2B | +4.8% |
| Q2 2025 | $37.2B | +1.8% |
| Q1 2025 | $35.5B | +6.6% |
| Q4 2024 | $42B | +7.6% |
| Q3 2024 | $35.5B | +5.2% |
BABA has the edge over HZO on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 7.2% | -6.9 points |
| Q1 2026 | -0.3% | -12 points |
| Q4 2025 | 7.1% | -7.6 points |
| Q3 2025 | 2.2% | -13 points |
| Q2 2025 | 14% | -0.7 points |
| Q1 2025 | 12% | +5.4 points |
| Q4 2024 | 15% | +6.1 points |
| Q3 2024 | 15% | 0 points |
BABA has the edge over HZO on profitability, with a higher operating margin.
HZO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $520.1M | -5.8% |
| Q2 2026 | $611.3M | -7% |
| Q1 2026 | $527.4M | -16% |
| Q4 2025 | $505.2M | +7.8% |
HZO's revenue has slid since its 2025 peak: $520M last quarter, down 5.8% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 6.1% | +12 points |
| Q1 2026 | 2% | -1.6 points |
| Q4 2025 | 1% | -7.4 points |
| Q3 2025 | 2.5% | N/A |
| Q2 2025 | -6.3% | N/A |
| Q1 2025 | 3.6% | N/A |
| Q4 2024 | 8.3% | N/A |
HZO's operating margin was 6.1% last quarter, up 12 points from the same quarter a year ago.
BABA Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$6.7B | -$4.1B |
| Q1 2026 | -$2.7B | +$1.5B |
| Q4 2025 | $1B | -90% |
| Q3 2025 | -$3.2B | -254% |
| Q2 2025 | -$2.7B | -182% |
| Q1 2025 | -$4.2B | -12231% |
| Q4 2024 | $10.4B | -4.8% |
| Q3 2024 | $2.1B | -62% |
BABA's free cash flow has turned negative after years in the green: −$11.6B over the past year.
HZO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $77.2M | +13% |
| Q1 2026 | $44.5M | -26% |
| Q4 2025 | $8.3M | +$172.7M |
HZO and BABA do not have enough comparable growth data to identify a winner.
BABA Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.5% | +11.1M shares |
| 1 year | +0.9% | +21.4M shares |
| 3 years | -6.2% | -161M shares |
| 5 years | -12% | -339M shares |
| Available history | -8.4% | -221M shares |
BABA has the edge over HZO on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2026 | — |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | $269.8M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | — |
| Q3 2024 | — |
BABA spent $270M buying back its own shares over the past year, after none the year before.
HZO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +5.1% | +1.1M shares |
| 1 year | +7.6% | +1.6M shares |
HZO has 23M diluted shares, up 7.6% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2025 | — |
| Q2 2025 | $15M |
BABA Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 0.5x | Very low |
| Q1 2026 | 0.5x | Very low |
| Q4 2025 | 0.6x | Very low |
| Q3 2025 | 0.8x | Very low |
| Q2 2025 | 0.2x | Very low |
| Q1 2025 | 0.3x | Very low |
| Q4 2024 | 0.1x | Very low |
| Q3 2024 | -0.2x | Net Cash |
BABA has the edge over HZO on leverage, with a lower net debt burden relative to earnings.
HZO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 6.8x | High |
| Q1 2026 | 22.5x | High |
| Q4 2025 | 18.3x | High |
| Q3 2025 | 11.3x | High |
| Q2 2025 | 10.4x | High |
| Q1 2025 | 5.1x | High |
| Q4 2024 | 5.3x | High |
HZO's net debt is about 6.8 years of its operating earnings (EBITDA), down from 10 years a year ago.
BABA Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 38.0 | Neutral |
| Stochastic | 12.7 | Oversold |
BABA's weekly RSI is 38 (neutral) and its Stochastic is 13 (oversold).
HZO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 78.2 | Overbought |
| Stochastic | 96.4 | Overbought |
HZO's weekly RSI is 78 (overbought) and its Stochastic is 96 (overbought).
BABA PE vs Consumer Cyclical Sector
| Metric | BABA | Sector median | Relative |
|---|---|---|---|
| PE | 21x | 18x | 19% above |
| PE % | 60 | 47 | 13 pts above |
BABA has the edge over HZO on valuation relative to its sector.
HZO PE vs Consumer Cyclical Sector
| Metric | HZO | Sector median | Relative |
|---|---|---|---|
| PE | 203x | 18x | 1,026% above |
| PE % | 100 | 47 | 53 pts above |
HZO has no meaningful PE right now: it lost money over the past year.
BABA Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $104.7 | 9.9% below |
| 20 week MA | $111.1 | 15% below |
| 50 week MA | $128.0 | 26% below |
| 100 week MA | $127.7 | 26% below |
| 200 week MA | $106.4 | 11% below |
BABA is in a downtrend: it's below all five of its weekly moving averages, and 11% below its 200-week average.
HZO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $52.6 | 0.5% above |
| 20 week MA | $47.2 | 12% above |
| 50 week MA | $36.4 | 45% above |
| 100 week MA | $30.6 | 72% above |
| 200 week MA | $31.1 | 70% above |
HZO has the edge over BABA on trend strength, trading above more of its moving averages.
BABA Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $215.5 | $222.0 | +3% |
| 2021 | $222.0 | $118.7 | -47% |
| 2022 | $118.7 | $85.7 | -28% |
| 2023 | $85.7 | $77.5 | -9.5% |
| 2024 | $77.5 | $85.1 | +9.7% |
| 2025 | $85.1 | $152.2 | +79% |
| 2026 YTD | $152.2 | $94.4 | -38% |
BABA has finished lower in three of the last six years. It's down 38% so far in 2026.
HZO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $16.7 | $37.8 | +127% |
| 2021 | $37.8 | $56.3 | +49% |
| 2022 | $56.3 | $31.0 | -45% |
| 2023 | $31.0 | $38.9 | +26% |
| 2024 | $38.9 | $27.8 | -29% |
| 2025 | $27.8 | $24.5 | -12% |
| 2026 YTD | $24.5 | $52.8 | +116% |
HZO has the edge over BABA on returns for 2026, with the stronger performance.